<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet13197</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-13197</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group></article-categories><title-group><article-title>Радиочастотная эхографическая мультиспектрометрия в диагностике остеопороза при пролактиноме</article-title><trans-title-group xml:lang="en"><trans-title>Radiofrequency echographic multi-spectrometry and prolactinoma: case report</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0327-4619</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дзеранова</surname><given-names>Л. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Shutova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дзеранова Лариса Константиновна, д.м.н.</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Aleksandra S. Shutova</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">dzeranovalk@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0047-7223</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шутова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Dzeranova</surname><given-names>L. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шутова Александра Сергеевна</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Larisa K. Dzeranova, ScD</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">shutova.aleksandra@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6539-466X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пигарова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pigarova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пигарова Екатерина Александровна, д.м.н.</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Ekaterina A. Pigarova, MD, PhD</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">kpigarova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7470-1676</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воротникова</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Vorotnikova</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Воротникова Светлана Юрьевна</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Svetlana Y. Vorotnikova, MD</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">bra_svetix@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1792-6419</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буйваленко</surname><given-names>У. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Buyvalenko</surname><given-names>U. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Буйваленко Ульяна Валерьевна</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Uliana V. Buyvalenko</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">ulibu@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5824-6490</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перепелова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Perepelova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Перепелова Маргарита Александровна</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Margarita A. Perepelova</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">margo.doktor@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1387-8536</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмин</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzmin</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузьмин Анатолий Геннадьевич, к.м.н.</p><p>117036, Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Anatoly G. Kuzmin, MD, PhD</p><p>11 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">kuzmin.anatoly@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ эндокринологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The National Medical Research Center for Endocrinology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>06</day><month>11</month><year>2024</year></pub-date><volume>21</volume><issue>4</issue><fpage>431</fpage><lpage>438</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Дзеранова Л.К., Шутова А.С., Пигарова Е.А., Воротникова С.Ю., Буйваленко У.В., Перепелова М.А., Кузьмин А.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Дзеранова Л.К., Шутова А.С., Пигарова Е.А., Воротникова С.Ю., Буйваленко У.В., Перепелова М.А., Кузьмин А.Г.</copyright-holder><copyright-holder xml:lang="en">Shutova A.S., Dzeranova L.K., Pigarova E.A., Vorotnikova S.Y., Buyvalenko U.V., Perepelova M.A., Kuzmin A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/13197">https://www.omet-endojournals.ru/jour/article/view/13197</self-uri><abstract><p>В случае пролактин-секретирующих аденом гипофиза внимание пациентов и врачей обращено на клинические проявления аденомы гипофиза, в том числе — на ассоциированные метаболические нарушения. Успешность консервативных методов лечения пролактином, разработка и внедрение в практику новых подходов к терапии агрессивных и резистентных аденом гипофиза позволяют сфокусироваться на неочевидных патологических состояниях, сопровождающих пролактин-секретирующие аденомы. В их числе — вторичное нарушение костного обмена со снижением минеральной плотности кости (МПК), приводящее к остеопорозу и низкоэнергетическим переломам. Залог эффективной профилактики и лечения остеопороза — своевременная и точная диагностика, однако не все методы определения МПК, разработанные к настоящему времени, могут быть охарактеризованы таким образом. В настоящей работе освещены вопросы использования новых методов диагностики остеопороза в контексте его высокого риска при гормонально-активных аденомах гипофиза, в частности при пролактиномах, на примере реального клинического случая.</p></abstract><trans-abstract xml:lang="en"><p>In case of prolactin-secreting pituitary adenomas, the attention of patients and physicians is drawn to the clinical manifestations of pituitary adenoma, including associated metabolic disorders. The success of conservative methods of treating prolactinomas, the development and implementation of new approaches to the treatment of aggressive and resistant pituitary adenomas allow us to focus on non-obvious pathological conditions accompanying prolactin-secreting adenomas. These include secondary bone metabolism disorders with decreased bone mineral density (BMD), leading to osteoporosis and low-traumatic fractures. The key to effective prevention and treatment of osteoporosis is timely and accurate diagnostics, but not all methods for determining BMD developed to date can be characterized in this way. This paper highlights the use of new methods for diagnosing osteoporosis in the context of its high risk in hormonally active pituitary adenomas, in particular in prolactinomas, using a real clinical case as an example</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеопороз</kwd><kwd>радиочастотная эхографическая мультиспектрометрия</kwd><kwd>рентгенденситометрия</kwd><kwd>REMS</kwd><kwd>пролактинома</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoporosis</kwd><kwd>radiofrequency echographic multi-spectrometry</kwd><kwd>dual-energy X-ray absorptiometry (DXA)</kwd><kwd>prolactinoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гиперпролактинемия в практике гинеколога: этиология, патогенез, клиника, диагностика, лечение / О.Р. Григорян, А.А. Ларина, Е.Н. Андреева, Г.А. Мельниченко // Проблемы репродукции. — 2013. — № 4. — С. 14-20. Иловайская И.А. Гиперпролактинемия в акушерско-гинекологической практике / И.А. Иловайская // Акушерство и гинекология. — 2017. — № 4. — С. 149-154.</mixed-citation><mixed-citation xml:lang="en">Giperprolaktinemiya v praktike ginekologa: etiologiya, patogenez, klinika, diagnostika, lechenie / OR Grigoryan, AA Larina, EN Andreeva, GA Mel'nichenko // Problemy reprodukcii. 2013;4:14-20. Ilovajskaya, IA. Giperprolaktinemiya v akushersko-ginekologicheskoj praktike / I.A. Ilovajskaya // Akusherstvo i ginekologiya. 2017;4:149-154 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tritos NA, Miller KK. Diagnosis and Management of Pituitary Adenomas: A Review. JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444. PMID: 37097352.</mixed-citation><mixed-citation xml:lang="en">Tritos NA, Miller KK. Diagnosis and Management of Pituitary Adenomas: A Review. JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444. PMID: 37097352.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Colao A. The prolactinoma. Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism. 2009;5(23):575-596</mixed-citation><mixed-citation xml:lang="en">Colao A. The prolactinoma. Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism. 2009;5(23):575-596</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Калмыкова З.А., Воротникова С.Ю., Федорова Н.С., Дзеранова Л.К., Пигарова Е.А., Воронцов А.В. Эффективность назначения высоких доз каберголина при лечении резистентных пролактином: клиническое наблюдение // Ожирение и метаболизм. — 2019. — Т.16. — №2. — С.89-94. doi: https://doi.org/10.14341/omet10243</mixed-citation><mixed-citation xml:lang="en">Kalmykova ZA, Vorotnikova SY, Fedorova NS, Dzeranova LK, Pigarova EA, Vorontsov .V. The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation. Obesity and metabolism. 2019;16(2):89-94. (In Russ.) doi: https://doi.org/10.14341/omet10243</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology &amp; Metabolism. 2011;96(2):273–88. doi: https://doi.org/10.1210/jc.2010-1692</mixed-citation><mixed-citation xml:lang="en">Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology &amp; Metabolism. 2011;96(2):273–88. doi: https://doi.org/10.1210/jc.2010-1692</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab. 2000;279:E1216–25</mixed-citation><mixed-citation xml:lang="en">Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab. 2000;279:E1216–25</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 2008;42:535–46</mixed-citation><mixed-citation xml:lang="en">Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 2008;42:535–46</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnamra N, Seemoung J. Effects of acute and long-term administration of prolactin on bone 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol. 1996;74:1157–65</mixed-citation><mixed-citation xml:lang="en">Krishnamra N, Seemoung J. Effects of acute and long-term administration of prolactin on bone 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol. 1996;74:1157–65</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, Krishnamra N. Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int. 2008;32:1126–35</mixed-citation><mixed-citation xml:lang="en">Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, Krishnamra N. Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int. 2008;32:1126–35</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mazziotti G, Frara S, Giustina A. Pituitary Diseases and Bone. Endocr Rev. 2018 Aug 1;39(4):440-488. doi: https://doi.org/10.1210/er.2018-00005</mixed-citation><mixed-citation xml:lang="en">Mazziotti G, Frara S, Giustina A. Pituitary Diseases and Bone. Endocr Rev. 2018 Aug 1;39(4):440-488. doi: https://doi.org/10.1210/er.2018-00005</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Naliato ECO, Farias MLF, Braucks GR, Costa FSR, Zylberberg D, Violante AHD. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest. 2005;28(3):12-17. doi: https://doi.org/10.1007/BF03345523</mixed-citation><mixed-citation xml:lang="en">Naliato ECO, Farias MLF, Braucks GR, Costa FSR, Zylberberg D, Violante AHD. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest. 2005;28(3):12-17. doi: https://doi.org/10.1007/BF03345523</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Y, Gan X, Luo P, et al. The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol. 2012;28(12):945-948. doi: https://doi.org/10.3109/09513590.2012.683080</mixed-citation><mixed-citation xml:lang="en">Zhao Y, Gan X, Luo P, et al. The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol. 2012;28(12):945-948. doi: https://doi.org/10.3109/09513590.2012.683080</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Belaya ZhE, Belova KYu, Biryukova EV, Dedov II, Dzeranova LK, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4-47. doi: https://doi.org/10.14341/osteo12930</mixed-citation><mixed-citation xml:lang="en">Belaya ZhE, Belova KYu, Biryukova EV, Dedov II, Dzeranova LK, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4-47. doi: https://doi.org/10.14341/osteo12930</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г., Пигарова Е.А., Поваляева А.А., и др. Проект федеральных клинических рекомендаций по диагностике, лечению и профилактике дефицита витамина D. // Остеопороз и остеопатии. — 2021. — Т. 24. — №4. — С. 4-26. doi: https://doi.org/10.14341/osteo12937</mixed-citation><mixed-citation xml:lang="en">Dedov II, Mel’nichenko GA, Mokrysheva NG, Pigarova EA, Povaliaeva AA, et al. Draft federal clinical practice guidelines for the diagnosis, treatment, and prevention of vitamin D deficiency. Osteoporosis and Bone Diseases. 2021;24(4):4-26. (In Russ.). doi: https://doi.org/10.14341/osteo12937</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В., Мельниченко Г.А., Дедов И.И. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы Эндокринологии. 2016;62(4):60-84. doi: https://doi.org/10.14341/probl201662460-84</mixed-citation><mixed-citation xml:lang="en">Pigarova EA, Rozhinskaya L.Ya., Belaya Zh.E., Dzeranova L.K., Karonova T.L., Ilyin A.V., Melnichenko G.A., Dedov I.I. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.) doi: https://doi.org/10.14341/probl201662460-84</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Гребенникова Т.А., Пигарова Е.А., и др. Краткое изложение клинических рекомендаций по диагностике и лечению остеопороза Российской ассоциации эндокринологов. // Остеопороз и остеопатии. — 2016. — Т. 19. — №3. — С. 28-36. doi: https://doi.org/10.14341/osteo2016328-36</mixed-citation><mixed-citation xml:lang="en">Melnichenko GA, Belaya ZhE, Rozhinskaya LYa, Grebennikova TA, Pigarova EA, et al. Summary of clinical guidelines for the diagnosis and treatment of osteoporosis of the Russian association of endocrinologists. Osteoporosis and Bone Diseases. 2016;19(3):28-36. (In Russ.) doi: https://doi.org/10.14341/osteo2016328-36</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fonseca H, Moreira-Gonçalves D, Coriolano H-JA, Duarte JA. Bone Quality: The Determinants of Bone Strength and Fragility. Sport Med. 2014;44(1):37-53. doi: https://doi.org/10.1007/s40279-013-0100-7</mixed-citation><mixed-citation xml:lang="en">Fonseca H, Moreira-Gonçalves D, Coriolano H-JA, Duarte JA. Bone Quality: The Determinants of Bone Strength and Fragility. Sport Med. 2014;44(1):37-53. doi: https://doi.org/10.1007/s40279-013-0100-7</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Caffarelli C, Tomai Pitinca MD, Al Refaie A, Ceccarelli E, Gonnelli S. Ability of radiofrequency echographic multispectrometry to identify osteoporosis status in elderly women with type 2 diabetes. Aging Clin Exp Res. 2022;34(1):121-127. doi: https://doi.org/10.1007/s40520-021-01889-w</mixed-citation><mixed-citation xml:lang="en">Caffarelli C, Tomai Pitinca MD, Al Refaie A, Ceccarelli E, Gonnelli S. Ability of radiofrequency echographic multispectrometry to identify osteoporosis status in elderly women with type 2 diabetes. Aging Clin Exp Res. 2022;34(1):121-127. doi: https://doi.org/10.1007/s40520-021-01889-w</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Conversano F, Franchini R, Greco A, et al. A Novel Ultrasound Methodology for Estimating Spine Mineral Density. Ultrasound Med Biol. 2015;41(1):281-300. doi: https://doi.org/10.1016/j.ultrasmedbio.2014.08.017</mixed-citation><mixed-citation xml:lang="en">Conversano F, Franchini R, Greco A, et al. A Novel Ultrasound Methodology for Estimating Spine Mineral Density. Ultrasound Med Biol. 2015;41(1):281-300. doi: https://doi.org/10.1016/j.ultrasmedbio.2014.08.017</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Di Paola M, Gatti D, Viapiana O, et al. Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int. 2019;30(2):391-402. doi: https://doi.org/10.1007/s00198-018-4686-3</mixed-citation><mixed-citation xml:lang="en">Di Paola M, Gatti D, Viapiana O, et al. Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int. 2019;30(2):391-402. doi: https://doi.org/10.1007/s00198-018-4686-3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
